The FDA Oncologic Drugs Advisory Committee earlier this week was asked to review two of the slowest-moving confirmatory trials.
Experts in pharmacology and lung cancer urged physicians to prescribe the Amgen agent Lumakras (sotorasib) at the lowest tested dose—240 mg—instead of the four times higher dose of 960 mg recommended by the sponsor.
As the third-largest nonprofit health system nationwide, Advocate Health treats nearly 50,000 new cancer cases annually. The integrated system has a unique opportunity to leverage its scale to advance complex cancer care and improve health outcomes across its various markets.
Liquid biopsy tests may someday upend screening as we know it. The promise of broad screening employing “multi-cancer detection” has spawned consortia and inspired enthusiastic opinion articles.
Joe W. Ramos was named director of the LSU LCMC Health Cancer Center.
Debra Friedman, E. Bronson Ingram Chair in Pediatric Oncology, was named deputy director of Vanderbilt-Ingram Cancer Center.
Benjamin Neel, former director of Perlmutter Cancer Center, is suing NYU Langone Medical Center, claiming unlawful termination, his attorneys announced.
Amidst the latest two-tiered continuing resolution signed by Congress Nov. 15—averting a government shutdown—cancer organizations are urging Congress to increase funding for cancer research.
The White House has established an initiative that aims to help federal agencies, companies, and philanthropic groups to close research gaps in women’s health care—including cancer.
Nathan Hubbard was named chief business officer at Flatiron Health.
